<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04328805</url>
  </required_header>
  <id_info>
    <org_study_id>CE0072015-02-05</org_study_id>
    <nct_id>NCT04328805</nct_id>
  </id_info>
  <brief_title>Pain Reduction and Changes in Upper Limb Function Produced by an Ibuprofen Treatment in Carpal Tunnel Syndrome.</brief_title>
  <official_title>Pain Reduction and Changes in Upper Limb Function Produced by Over the Counter Oral Ibuprofen Versus the Lack of Treatment, in Carpal Tunnel Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Europea de Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Europea de Madrid</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the present investigation the pain reduction effect of an oral ibuprofen treatment will be
      compared to those produced by the absence of treatment, in subjects who suffer the signs and
      symptoms of carpal tunnel syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present randomized clinical trial will perform a comparison of the pain reduction effects
      produced by an oral ibuprofen pharmacological treatment and the lack of treatment in subjects
      diagnosed with carpal tunnel syndrome. Effects over the functionality of the affected upper
      limb will be evaluated and compared. Subjects will be invited to participate and randomly
      allocated to 2 different groups.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distal upper limb pain</measure>
    <time_frame>Changes from baseline (measured immediately before the application of each treatment) at 60 minutes after the application of treatment. Measures at baseline and after treatment will be performed 1 day a week during 4 weeks.</time_frame>
    <description>Assessed through the visual analog scale (VAS). The VAS is a psychometric response scale. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured.The VAS is the most frequently used method to assess pain intensity. The scale will be displayed as a horizontal 100-mm line labelled at each end by descriptors such as 'no pain' (the minimum and best outcome possible) and 'worse pain ever' (maximum and worst outcome possible). The participant will mark the line to indicate pain severity and it is simply quantified by measuring the distance in millimeters from 0 (no pain) to the patient's marked rating.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Upper limb function</measure>
    <time_frame>Changes from baseline (measured immediately before the application of the first treatment), and at 60 minutes after the application of the last treatment</time_frame>
    <description>Assessed through the quick Quick Disabilities of the Arm, Shoulder and Hand questionary (QuickDASH), which is a shortened version of the 30-item Disabilities of the Arm, Shoulder and Hand (DASH) instrument.The instrument administered to the participants will be a self-report questionnaire, that will rate the difficulty and interference of daily life on a 5 point Likert scale. At least 10 of the 11 items must be completed for a score to be calculated and the scores range from 0 (no disability) to 100 (most severe disability).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Carpal Tunnel Syndrome</condition>
  <condition>Ibuprofen</condition>
  <condition>Pain Management</condition>
  <condition>Pain, Chronic</condition>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet pharmaceutical treatment. Participants will be treated with a maximum of 1200 mg per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Waiting list control group. Participants that belong to the no intervention arm will be assigned to a waiting list to receive treatment. The participants will not receive treatment for carpal tunnel syndrome during a time lapse of 4 weeks. After this period of time, participants will begin the best treatment available.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen tablets</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Ibuprofen</arm_group_label>
    <other_name>Advil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must be medically diagnosed with unilateral carpal tunnel syndrome (with
             confirmative electrodiagnostic findings).

          -  Full understanding of written and spoken Spanish (language).

          -  Participants must freely consent to participate.

          -  The presence of positive Phalen and Tinel signs.

          -  The presence of carpal tunnel syndrome signs and symptoms.

        Exclusion Criteria:

        • The lack to meet inclusion criterions, the presence of cognitive impairment, tumors,
        cancer, recent (affected) upper limb surgery or trauma, pregnancy, , deformities of the
        (affected) upper limb, recent skin injuries or infections (in the affected upper limb),
        autoimmune inflammatory conditions or flu type symptoms, allergy (or contraindication) to
        non steroidal anti inflammatory drugs (NSAID), and also: participants must not be (during
        the present investigation) under any type of pain reducing treatment (conservative,
        homeopathic, invasive or not invasive).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Perez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>INSALUD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francisco H Unda, PhD</last_name>
    <phone>0034982410289</phone>
    <email>5299559@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centro Médico y de Especialidades Pediátricas Dr. José Gregorio Hernández</name>
      <address>
        <city>San Diego</city>
        <state>Carabobo</state>
        <zip>02006</zip>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Venezuela</country>
  </location_countries>
  <reference>
    <citation>Ilyas AM, Miller AJ, Graham JG, Matzon JL. A Prospective, Randomized, Double-Blinded Trial Comparing Acetaminophen, Ibuprofen, and Oxycodone for Pain Management After Hand Surgery. Orthopedics. 2019 Mar 1;42(2):110-115. doi: 10.3928/01477447-20190221-02. Epub 2019 Feb 27.</citation>
    <PMID>30810754</PMID>
  </reference>
  <reference>
    <citation>Weinheimer K, Michelotti B, Silver J, Taylor K, Payatakes A. A Prospective, Randomized, Double-Blinded Controlled Trial Comparing Ibuprofen and Acetaminophen Versus Hydrocodone and Acetaminophen for Soft Tissue Hand Procedures. J Hand Surg Am. 2019 May;44(5):387-393. doi: 10.1016/j.jhsa.2018.10.014. Epub 2018 Nov 27.</citation>
    <PMID>30502019</PMID>
  </reference>
  <reference>
    <citation>Riasi H, Rajabpour Sanati A, Salehi F, Salehian H, Ghaemi K. Analyzing the therapeutic effects of short wrist splint in patients with carpal tunnel syndrome (CTS) under ibuprofen treatment from an EMG-NCV perspective. J Med Life. 2015;8(Spec Iss 4):154-158.</citation>
    <PMID>28316723</PMID>
  </reference>
  <reference>
    <citation>Hadianfard M, Bazrafshan E, Momeninejad H, Jahani N. Efficacies of Acupuncture and Anti-inflammatory Treatment for Carpal Tunnel Syndrome. J Acupunct Meridian Stud. 2015 Oct;8(5):229-35. doi: 10.1016/j.jams.2014.11.005. Epub 2014 Nov 29.</citation>
    <PMID>26433799</PMID>
  </reference>
  <reference>
    <citation>Davis PT, Hulbert JR, Kassak KM, Meyer JJ. Comparative efficacy of conservative medical and chiropractic treatments for carpal tunnel syndrome: a randomized clinical trail. J Manipulative Physiol Ther. 1998 Jun;21(5):317-26.</citation>
    <PMID>9627862</PMID>
  </reference>
  <reference>
    <citation>Giuliani E, Bianchi A, Marcuzzi A, Landi A, Barbieri A. Ibuprofen timing for hand surgery in ambulatory care. Acta Ortop Bras. 2015 Jul-Aug;23(4):188-91. doi: 10.1590/1413-78522015230400736.</citation>
    <PMID>26327799</PMID>
  </reference>
  <reference>
    <citation>Banta CA. A prospective, nonrandomized study of iontophoresis, wrist splinting, and antiinflammatory medication in the treatment of early-mild carpal tunnel syndrome. J Occup Med. 1994 Feb;36(2):166-8.</citation>
    <PMID>8176515</PMID>
  </reference>
  <reference>
    <citation>Dosenovic S, Jelicic Kadic A, Miljanovic M, Biocic M, Boric K, Cavar M, Markovina N, Vucic K, Puljak L. Interventions for Neuropathic Pain: An Overview of Systematic Reviews. Anesth Analg. 2017 Aug;125(2):643-652. doi: 10.1213/ANE.0000000000001998. Review.</citation>
    <PMID>28731977</PMID>
  </reference>
  <reference>
    <citation>Calvo-Lobo C, Unda-Solano F, López-López D, Sanz-Corbalán I, Romero-Morales C, Palomo-López P, Seco-Calvo J, Rodríguez-Sanz D. Is pharmacologic treatment better than neural mobilization for cervicobrachial pain? A randomized clinical trial. Int J Med Sci. 2018 Mar 8;15(5):456-465. doi: 10.7150/ijms.23525. eCollection 2018.</citation>
    <PMID>29559834</PMID>
  </reference>
  <reference>
    <citation>Rodríguez-Sanz D, López-López D, Unda-Solano F, Romero-Morales C, Sanz-Corbalán I, Beltran-Alacreu H, Calvo-Lobo C. Effects of Median Nerve Neural Mobilization in Treating Cervicobrachial Pain: A Randomized Waiting List-Controlled Clinical Trial. Pain Pract. 2018 Apr;18(4):431-442. doi: 10.1111/papr.12614. Epub 2017 Nov 20.</citation>
    <PMID>28734105</PMID>
  </reference>
  <reference>
    <citation>Eren Y, Yavasoglu NG, Comoglu SS. The relationship between QDASH scale and clinical, electrophysiological findings in carpal tunnel syndrome. Adv Clin Exp Med. 2018 Jan;27(1):71-75. doi: 10.17219/acem/67947.</citation>
    <PMID>29521045</PMID>
  </reference>
  <reference>
    <citation>Shin D, Lee SJ, Ha YM, Choi YS, Kim JW, Park SR, Park MK. Pharmacokinetic and pharmacodynamic evaluation according to absorption differences in three formulations of ibuprofen. Drug Des Devel Ther. 2017 Jan 4;11:135-141. doi: 10.2147/DDDT.S121633. eCollection 2017.</citation>
    <PMID>28115830</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 29, 2020</study_first_submitted>
  <study_first_submitted_qc>March 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>March 29, 2020</last_update_submitted>
  <last_update_submitted_qc>March 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Europea de Madrid</investigator_affiliation>
    <investigator_full_name>Francisco Unda Solano</investigator_full_name>
    <investigator_title>Biomedicine Doctorate Program Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carpal Tunnel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

